# PT-141: An Endogenous Hormone, Redesigned Until It Survived > PT-141 (Bremelanotide): Research Overview — Primitive Peptides — PT-141 in Research Peptide Fundamentals: a cyclised, substituted analogue of alpha-MSH engineered to outlast the hormone it came from. Mechanism, the Phase 3 record, long-term tolerability, and the off-target costs of that engineering. **03 / ENDOGENOUS ORIGINS** Bremelanotide is the core of alpha-MSH closed into a ring, substituted at two positions and stabilised — and every modification that made it a usable drug is a step away from the molecule the body actually releases. ## Abstract, in plain English **PT-141**, generic name **bremelanotide**, comes from the same human hormone as [KPV](/kpv) — alpha-melanocyte-stimulating hormone — but from a different part of it and by a very different method. Where KPV is simply the tail of the hormone cut off and used as-is, bremelanotide is the middle of the hormone rebuilt. Chemists took the core sequence, joined two of its side chains together to lock it into a ring, and swapped two amino acids for unnatural ones. The purpose of all of that was durability: the natural hormone is broken down in the body within minutes, which makes it useless as a medicine. The rebuilt molecule works on **melanocortin receptors** in the brain, mainly one called MC4R, which sits in circuits governing sexual desire. That is unlike erectile-dysfunction pills, which act on blood vessels in the body rather than on the brain. It is approved in the United States for one specific condition in one specific population, and it is marketed as Vyleesi. The cost of the redesign is that MC4R is not the only receptor in the family it activates, and desire is not the only thing that family controls. ## What it is Bremelanotide is a synthetic cyclic heptapeptide lactam analogue of alpha-MSH, sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge formed between the aspartate and lysine side chains. It is a structural relative and metabolite of melanotan II, differing in that the C-terminal amide is replaced by a carboxylic acid. Three design decisions are visible in that description, and each one is a deliberate departure from the endogenous molecule. The **cyclisation** removes the flexible linear backbone that peptidases attack most readily. The **Nle** substitution replaces methionine, which is prone to oxidation. The **D-Phe** substitution installs a mirror-image amino acid that mammalian enzymes are poor at cleaving. None of these features exists in alpha-MSH. All of them exist because alpha-MSH does not last. The result is a molecule with a measurable, drug-like pharmacokinetic profile: the US prescribing information reports a terminal half-life of about 2.7 hours (range 1.9 to 4.0), a volume of distribution of 25.0 L, clearance of 6.5 L per hour, and renal and faecal excretion of 64.8% and 22.8% respectively [17]. Regulatory position is bifurcated and the distinction matters. Bremelanotide was approved by the FDA on 21 June 2019 for acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women, and is not approved for men, for postmenopausal women, or to enhance sexual performance [17]. Material sold online as "PT-141 research chemical" sits outside that approval entirely, with no regulatory oversight of identity, purity or concentration. ## How it works Bremelanotide activates central melanocortin receptors, chiefly MC4R and to a lesser extent MC3R, which are concentrated in the hypothalamus and limbic system. Stimulating MC4R in hypothalamic circuits such as the medial preoptic area is thought to engage dopaminergic pathways governing sexual desire and arousal. The contrast with PDE-5 inhibitors is mechanistic rather than rhetorical: those act peripherally on vascular smooth muscle, while this acts centrally on the neural circuitry of sexual motivation. Human neuroimaging supports the central account. In a randomised, double-blind, placebo-controlled crossover fMRI study of 31 premenopausal women with HSDD, MC4R agonism significantly increased sexual desire for up to 24 hours and altered task-based brain processing of erotic stimuli, enhancing amygdala-insula functional connectivity and cerebellar and supplementary-motor activity [14]. The circuit involved is not, however, the obvious one. In female Syrian hamsters, MC3R and MC4R mRNA was concentrated in ventral tegmental area dopamine neurons, yet neither low- nor high-dose bremelanotide altered melanocortin-receptor mRNA expression in the mesolimbic dopamine system, and bremelanotide did not enhance sexual reward measured by conditioned place preference — a negative result suggesting it does not act on the VTA-to-nucleus-accumbens reward pathway [13]. Two common misconceptions are worth retiring. Bremelanotide does not act through the hypothalamic-pituitary-gonadal axis and does not directly raise testosterone, and it is not a PDE-5 inhibitor and does not act on vascular smooth muscle. ## What the research shows The pivotal evidence is two identical Phase 3 randomised controlled trials, RECONNECT, enrolling 1,267 premenopausal women with HSDD. Bremelanotide 1.75 mg subcutaneously as needed produced a statistically significant improvement in sexual desire (integrated FSFI-desire +0.35, P<.001) and a reduction in desire-related distress (integrated FSDS-DAO item 13 −0.33, P<.001) versus placebo over 24 weeks, meeting the co-primary endpoints in both trials; the most common adverse events were nausea, flushing and headache [15]. The 52-week open-label extension enrolled 684 women. No new safety signals emerged and the improvement in sexual desire was sustained. The most common drug-related treatment-emergent adverse events were nausea at 40.4%, flushing at 20.6% and headache at 12.0% [16]. The approved label rounds out the quantitative picture: a 1.75 mg subcutaneous as-needed dose, no more than one dose in 24 hours and no more than eight doses per month, with a warning on transient blood-pressure increase and a contraindication in uncontrolled hypertension or known cardiovascular disease [17]. The critical reading deserves equal space. Re-analyses have argued that the trial effects on desire and distress, while statistically significant, are small, and have questioned their clinical meaningfulness and the outcome measures used. A 2023 Expression of Concern was issued for a 2008 erectile-dysfunction salvage study, whose findings are best treated as disputed. And the hamster study above is a reminder that the mechanistic story is still being assembled rather than settled [13]. ## Reported effects, cautions and safety The accounts in this first part are **anecdotal, not clinical evidence** — they are drawn from research-use communities, patient-review sites and clinic write-ups, they carry no controls and no verification, and no dose is attached to any of them. On the benefit side, the most commonly reported experience is a stronger sense of sexual desire and wanting that is described as beginning in the head rather than the body — an increase in interest and motivation rather than a physical response. Greater physical arousal and heightened sensitivity to touch are frequently described, sometimes building without direct stimulation, and easier or more intense orgasm is reported as a secondary effect that varies widely between individuals. In the off-label male research-use community, spontaneous erections and stronger sexual interest are frequently reported, with the urge described as arriving first. A stronger sense of emotional closeness during intimacy is occasionally reported, and many accounts note a delayed onset — commonly half an hour to a few hours — with a long window of effect, which some describe as convenient and others as difficult to plan around. On the other side, complete non-response is a recurring and honestly reported outcome, sometimes accompanied by side effects without any benefit. Nausea is by far the most common complaint and the one most likely to end use; flushing and warmth, headache, and injection-site redness or soreness are all frequently reported. Tingling or pins-and-needles, restless legs, unusually sensitive skin, a brief feeling of being on edge, and fatigue or drowsiness are occasionally described. With repeated frequent use, some accounts report darkening of skin, face or gums, new or darker freckles and darkening of existing moles, with a minority reporting that the darkening did not fully fade after stopping. The documented safety cautions that follow are drawn from clinical sources rather than from reports. - **Approved for one population only.** Bremelanotide is approved in the United States solely for acquired, generalised HSDD in premenopausal women; use in men, in postmenopausal women, or for sexual performance is off-label and outside the studied population [17][15]. - **Transient blood-pressure rise.** A short-lived increase in blood pressure follows dosing, with a matching small fall in heart rate, before returning to baseline within hours; the label contraindicates use in uncontrolled hypertension or known cardiovascular disease [17]. - **Nausea is common enough to limit use.** It affected roughly 40% of participants over long-term use and is a leading reason for discontinuation, ranging from mild and brief to vomiting [16][15]. - **Pigmentary change with frequent dosing.** Because the compound also activates pigment-driving receptors, repeated frequent dosing can darken the face, gums and breasts and alter moles or freckles, more likely in people with darker baseline skin and not always fully reversible; the labelled limit on dosing frequency exists partly to reduce this risk [17]. - **Liver signal.** The NIH LiverTox monograph notes mild rises in liver-related blood markers and, rarely, clinically apparent liver injury. - **Unregulated supply.** Material sold as "PT-141 research chemical" has no verified identity, purity or concentration; forensic testing of black-market melanocortin peptides confirms unregulated product circulates, and case reports of self-injected related peptides describe serious harm including severe muscle breakdown. - **Appetite and weight are an off-target effect, not a use.** MC4R also helps regulate appetite, and high-frequency research dosing reduced food intake and body weight — a pharmacological consequence to be aware of rather than an approved indication. - **Pregnancy and breastfeeding are unsupported.** No controlled human data establishes the safety of a centrally acting hormone-pathway agent of this kind in pregnancy or lactation, and no citation in this corpus establishes it. ## Where it fits in these origins Bremelanotide is the strongest argument on this site against reading endogenous origin as a safety credential, because it is the entry where the origin is real, the engineering is excellent, and the off-target costs are documented in an approved label rather than inferred. The hormone it descends from is genuinely human. The redesign genuinely worked: cyclisation and two unnatural substitutions bought a terminal half-life of about 2.7 hours where the native molecule lasts minutes [17], and that durability is what made a randomised trial possible at all [15]. But melanocortin receptors are a family, and a molecule engineered to persist for hours engages more of that family, for longer, than a rapidly cleared endogenous pulse ever does. MC1R activation is why pigmentation changes appear with frequent dosing [17]. MC4R expression in appetite circuits is why food intake and body weight moved in high-frequency research dosing. Neither is an impurity or a manufacturing defect. Both are the endogenous receptor system doing exactly what it does, addressed at a duration and frequency physiology does not produce. Set against [KPV](/kpv), the pair is instructive: one parent hormone, two derivatives, opposite design philosophies — subtract everything versus rebuild the core — and two entirely different pharmacological profiles. Shared ancestry predicted neither of them. --- Primitive Peptides traces four research compounds back to the molecules the body makes on its own, and treats endogenous origin as a starting hypothesis rather than a safety claim — a literature digest, not a clinic, a vendor, or a source of dosing advice.